1. Home
  2. HFRO vs DMAC Comparison

HFRO vs DMAC Comparison

Compare HFRO & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HFRO
  • DMAC
  • Stock Information
  • Founded
  • HFRO 2000
  • DMAC 2000
  • Country
  • HFRO United States
  • DMAC United States
  • Employees
  • HFRO N/A
  • DMAC N/A
  • Industry
  • HFRO Finance/Investors Services
  • DMAC Biotechnology: Pharmaceutical Preparations
  • Sector
  • HFRO Finance
  • DMAC Health Care
  • Exchange
  • HFRO Nasdaq
  • DMAC Nasdaq
  • Market Cap
  • HFRO 287.7M
  • DMAC 260.0M
  • IPO Year
  • HFRO N/A
  • DMAC N/A
  • Fundamental
  • Price
  • HFRO $6.02
  • DMAC $6.03
  • Analyst Decision
  • HFRO
  • DMAC Strong Buy
  • Analyst Count
  • HFRO 0
  • DMAC 4
  • Target Price
  • HFRO N/A
  • DMAC $10.75
  • AVG Volume (30 Days)
  • HFRO 179.8K
  • DMAC 424.1K
  • Earning Date
  • HFRO 01-01-0001
  • DMAC 08-12-2025
  • Dividend Yield
  • HFRO 8.87%
  • DMAC N/A
  • EPS Growth
  • HFRO N/A
  • DMAC N/A
  • EPS
  • HFRO N/A
  • DMAC N/A
  • Revenue
  • HFRO N/A
  • DMAC N/A
  • Revenue This Year
  • HFRO N/A
  • DMAC N/A
  • Revenue Next Year
  • HFRO N/A
  • DMAC N/A
  • P/E Ratio
  • HFRO N/A
  • DMAC N/A
  • Revenue Growth
  • HFRO N/A
  • DMAC N/A
  • 52 Week Low
  • HFRO $4.24
  • DMAC $3.19
  • 52 Week High
  • HFRO $6.45
  • DMAC $6.82
  • Technical
  • Relative Strength Index (RSI)
  • HFRO 79.30
  • DMAC 72.14
  • Support Level
  • HFRO $5.19
  • DMAC $4.39
  • Resistance Level
  • HFRO $6.04
  • DMAC $6.40
  • Average True Range (ATR)
  • HFRO 0.11
  • DMAC 0.43
  • MACD
  • HFRO 0.05
  • DMAC 0.15
  • Stochastic Oscillator
  • HFRO 97.06
  • DMAC 84.49

About HFRO Highland Opportunities and Income Fund of Beneficial Interest

Highland Opportunities and Income Fund is a non-diversified, closed-end management investment company. Its investment objective is to Income Fund seeks growth of capital along with income. It focuses on making investments in real estate securities, including Reits, secured and unsecured fixed-rate loans and corporate bonds, mezzanine securities, structured products, convertible and preferred securities and equities (public and private), and floating rate securities.

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Share on Social Networks: